![]() | |
Clinical data | |
---|---|
Trade names | Jeselhy |
Other names | TAS 116 |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C25H26N8O |
Molar mass | 454.538 g·mol−1 |
3D model ( JSmol) | |
|
Pimitespib (trade name Jeselhy) is a drug for the treatment of gastrointestinal stromal tumors. [1] It was discovered and developed by Taiho Pharmaceutical Co. [2] The mechanism of action of pimitespib involves inhibition of heat shock protein 90 (Hsp90). [3]
In June 2022, it received approval in Japan for gastrointestinal stromal tumors that have progressed after chemotherapy. [4]
![]() | |
Clinical data | |
---|---|
Trade names | Jeselhy |
Other names | TAS 116 |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C25H26N8O |
Molar mass | 454.538 g·mol−1 |
3D model ( JSmol) | |
|
Pimitespib (trade name Jeselhy) is a drug for the treatment of gastrointestinal stromal tumors. [1] It was discovered and developed by Taiho Pharmaceutical Co. [2] The mechanism of action of pimitespib involves inhibition of heat shock protein 90 (Hsp90). [3]
In June 2022, it received approval in Japan for gastrointestinal stromal tumors that have progressed after chemotherapy. [4]